medicine-news-1/formatta-presents-forms-driven-business-process-optimization-webinar-for-healthcare-on-thursday--november-19-at-1-p-m--eastern--60581-2/;msg90356

Breaking Biology Technology:Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2 Cell Biosciences Acquires Protein Forest 2 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4 Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2 Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3

[0] Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry [0] Cell Biosciences Acquires Protein Forest [0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A [0] Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2 Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3 For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2 For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3 HealthFitness Announces Third Quarter 2009 Financial Results 60712 1 HealthFitness Announces Third Quarter 2009 Financial Results 60712 2 HealthFitness Announces Third Quarter 2009 Financial Results 60712 3 HealthFitness Announces Third Quarter 2009 Financial Results 60712 4 HealthFitness Announces Third Quarter 2009 Financial Results 60712 5 HealthFitness Announces Third Quarter 2009 Financial Results 60712 6 HealthFitness Announces Third Quarter 2009 Financial Results 60712 7 HealthFitness Announces Third Quarter 2009 Financial Results 60712 8 HealthFitness Announces Third Quarter 2009 Financial Results 60712 9 HealthFitness Announces Third Quarter 2009 Financial Results 60712 10 HealthFitness Announces Third Quarter 2009 Financial Results 60712 11 Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 1 Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 2 Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 3 Zyngenia Inc Raises 2410 Million in Series A Funding 14724 1 Zyngenia Inc Raises 2410 Million in Series A Funding 14724 2 Zyngenia Inc Raises 2410 Million in Series A Funding 14724 3 Zyngenia Inc Raises 2410 Million in Series A Funding 14724 4

[0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day [0] For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain